Tango Therapeutics, Inc. (TNGX) Misses Q3 EPS by 7c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.14), $0.07 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $53.81 million versus the consensus estimate of $53.8 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance
• General Electric wins $2.9B Navy engine contract from DoD